

**An Important Message from
The Texas Health and Human Services Commission (HHSC)**

**Change in Preferred Drug List Status for Antihyperuricemics Drug Class
Effective April 22, 2024**

Background:

The manufacturer of brand name Colcrys products, Takeda Pharmaceuticals, confirmed these products were discontinued on Dec. 31, 2023, and some supplies of the products will remain available until exhausted from the market.

Key Details:

HHSC will remove the non-preferred status from brand name Mitigare products on the preferred drug list (PDL). The preferred status of brand name Colcrys products will not change and will allow pharmacies to use the existing stock of these medications.

HHSC will remove the non-preferred status for the following drugs, effective April 22, 2024.

NDC	Label Name
59467031801	MITIGARE 0.6 MG CAPSULE
59467031810	MITIGARE 0.6 MG CAPSULE
59467031830	MITIGARE 0.6 MG CAPSULE

These changes will allow providers to prescribe the brand name Mitigare products without requiring a PDL prior authorization and continue accessing necessary medication for clients. UnitedHealthcare® Community Plan will make this change by **April 25, 2024**.

Questions?

Please contact your physician advocate or call UnitedHealthcare Provider Services, toll-free, at 888-887-9003, 8 a.m.–6 p.m. CT, Monday–Friday.